Prosecution Insights
Last updated: April 19, 2026
Application No. 18/253,094

ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4

Non-Final OA §DP
Filed
May 16, 2023
Examiner
SOLOLA, TAOFIQ A
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
VANDERBILT UNIVERSITY
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
92%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
1095 granted / 1464 resolved
+14.8% vs TC avg
Strong +17% interview lift
Without
With
+16.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
19 currently pending
Career history
1483
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
29.5%
-10.5% vs TC avg
§102
15.6%
-24.4% vs TC avg
§112
33.2%
-6.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1464 resolved cases

Office Action

§DP
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 3, 5-6, 9-14, 16, 18-20, 23-27, 30, are pending in this application. Claims 2, 4, 7-8, 15, 17, 21-22, 28-29, 31-33, are deleted. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1, 3, 5-6, 9-14, 16, 18-20, 23-27, 30, are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20, of U.S. patent No. 11,299,481, and claims 1-20, of US 11,820,757. Although the claims at issue are not identical, they are not patentably distinct from each other because, the instant claims are claimed in the patents. The difference is the scope of the compounds. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, whose telephone number is (571) 272-0709. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andy Kosar, can be reached on (571) 272-0913. The fax phone number for this Group is (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600. /TAOFIQ A SOLOLA/ Primary Examiner, Art Unit 1625 August 26, 2025
Read full office action

Prosecution Timeline

May 16, 2023
Application Filed
Sep 02, 2025
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595242
PROCESS AND DEVICE FOR PREPARING TRIOXANE FROM METHANOL
2y 5m to grant Granted Apr 07, 2026
Patent 12583827
PRODUCTS OBTAINED BY THE CONVERSION OF GLYCOLALDEHYDE DERIVATIVES AND AMINATING AGENTS AND THEIR CONVERSION TO ETHYLENEAMINES AND ETHANOLAMINES
2y 5m to grant Granted Mar 24, 2026
Patent 12577256
ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME
2y 5m to grant Granted Mar 17, 2026
Patent 12570667
NOVEL COMPOUNDS WITH ANTIBACTERIAL AND ANTI VIRAL ACTIVITIES
2y 5m to grant Granted Mar 10, 2026
Patent 12558674
PROCESS FOR PRODUCING A SILVER-BASED EPOXIDATION CATALYST
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
92%
With Interview (+16.9%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 1464 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month